{
 "ticker": "THNR",
 "name": "Amplify Weight Loss Drug & Treatment ETF",
 "issuer": "Amplify",
 "desk": "themes",
 "url": "https://etfiq.com/funds/thnr",
 "html": "https://etfiq.com/funds/thnr",
 "markdown": "https://etfiq.com/funds/thnr.md",
 "as_of": "2026-09-11",
 "verdict": "THNR holds 22 stocks, and 64% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "36.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "THNR, already in the S&P 500: 36.0%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "96.7%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "THNR, active share vs the S&P 500: 96.7%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "62.3%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "THNR, top ten holdings: 62.3%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+11.3%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "THNR, total return, 1 year: +11.3%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$5m",
   "source": "issuer page, as of Sep 11, 2026",
   "as_of": "2026-09-11",
   "sentence": "THNR, net assets: $5m (issuer page, as of Sep 11, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.59%",
   "source": "485BPOS XBRL, Jan 28, 2026",
   "as_of": "2026-09-11",
   "sentence": "THNR, expense ratio: 0.59% (485BPOS XBRL, Jan 28, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Healthcare innovation and GLP-1",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "May 21, 2024",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "36.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "96.7%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "11.3%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "98.9%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "62.3%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "22",
   "source": null
  },
  {
   "key": "holdings_published_for",
   "label": "Holdings published for",
   "value": "Sep 14, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "Novo Nordisk A/S 8.8%, Eli Lilly & Co 8.7%, Regeneron Pharmaceuticals Inc 6.2%, Innovent Biologics Inc 6.0%, Scholar Rock Holding Corp 5.8%, CSPC Pharmaceutical Group Ltd 5.7%, Merck & Co Inc 5.6%, AbbVie Inc 5.3%, Arrowhead Pharmaceuticals Inc 5.2%, Amgen Inc 5.1%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$5m",
   "source": "issuer page, as of Sep 11, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22128.3%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.59%",
   "source": "485BPOS XBRL, Jan 28, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.61%",
   "source": "ETFIQ"
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+4.8%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+1.5 pts",
   "Gap to Nasdaq-100": "+5.6 pts"
  },
  {
   "window": "6 months",
   "Total return": "+5.3%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "\u221210.7 pts",
   "Gap to Nasdaq-100": "\u221215.4 pts"
  },
  {
   "window": "1 year",
   "Total return": "+11.3%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "\u22126.2 pts",
   "Gap to Nasdaq-100": "\u221211.7 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+3.4%",
   "S&P 500": "+47.7%",
   "Gap to S&P 500": "\u221244.3 pts",
   "Gap to Nasdaq-100": "\u221255.3 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of THNR is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 14, 2026, 36% of THNR by weight is stocks the S&P 500 already holds. Its active share against the index is 97%, so that share is the part doing something different."
  },
  {
   "q": "What does THNR hold?",
   "a": "22 positions as published by its issuer for Sep 14, 2026, with the top ten at 62% of the fund. The largest are Novo Nordisk A/S at 8.8%, Eli Lilly & Co at 8.7%, Regeneron Pharmaceuticals Inc at 6.2%."
  },
  {
   "q": "Has THNR beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 THNR returned +11.3% with distributions reinvested, against +17.5% for the S&P 500, so it finished behind the index by 6.2 points."
  },
  {
   "q": "What does THNR cost?",
   "a": "The prospectus expense ratio is 0.59% a year. Because 97% of the fund differs from the S&P 500, the fee on that differing part works out at 0.61%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}